ProShare Advisors LLC Lowers Holdings in AbbVie Inc. $ABBV

ProShare Advisors LLC trimmed its holdings in AbbVie Inc. (NYSE:ABBV) by 2.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,189,585 shares of the company’s stock after selling 25,387 shares during the quarter. AbbVie makes up approximately 0.6% of ProShare Advisors LLC’s holdings, making the stock its 21st biggest position. ProShare Advisors LLC owned 0.07% of AbbVie worth $275,437,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Evolution Wealth Management Inc. bought a new position in shares of AbbVie during the 2nd quarter valued at about $26,000. Spurstone Advisory Services LLC bought a new stake in shares of AbbVie in the second quarter worth about $28,000. Financial Gravity Companies Inc. purchased a new stake in shares of AbbVie in the second quarter worth about $36,000. Delos Wealth Advisors LLC bought a new position in AbbVie during the second quarter valued at approximately $39,000. Finally, Access Investment Management LLC purchased a new position in AbbVie during the 2nd quarter valued at approximately $44,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Trading Up 2.0%

ABBV stock opened at $223.50 on Monday. The stock has a market cap of $395.01 billion, a PE ratio of 94.70, a P/E/G ratio of 0.85 and a beta of 0.35. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The company has a 50-day moving average price of $223.74 and a 200 day moving average price of $219.84.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter last year, the firm earned $2.16 earnings per share. The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Sell-side analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Morgan Stanley raised its price target to $270 and kept an “overweight” call, signaling institutional analyst conviction that AbbVie has double‑digit upside from current levels. Read More.
• Positive Sentiment: Company forecasts for full‑year 2026 profit came in above estimates, driven by strong sales of newer immunology drugs (Skyrizi, Rinvoq), supporting the case for continued top‑line and earnings growth. Read More.
• Positive Sentiment: Market commentary and some analysts view the post‑earnings pullback as a buying opportunity, pointing to institutional accumulation, durable cash flow, and a strong dividend as anchors for medium‑term returns. Read More.
• Positive Sentiment: New real‑world Rinvoq data from Japan bolsters the drug’s addressable market for ankylosing spondylitis and reinforces growth prospects for AbbVie’s immunology franchise. Read More.
• Neutral Sentiment: Management framed the earnings call around “new growth engines” — Skyrizi/Rinvoq and other launches taking the lead in driving growth, which supports the long‑term story but doesn’t eliminate near‑term volatility. Read More.
• Neutral Sentiment: Q4 results beat on revenue and showed strong margin/earnings leverage, confirming product momentum even as some segments face headwinds. Read More.
• Negative Sentiment: Shares initially gapped down after the print as investors focused on a softer-than‑expected Q1 EPS and revenue outlook despite the quarter’s beats — a classic near‑term reaction to guidance misses. Read More.
• Negative Sentiment: AbbVie set Q1 2026 EPS guidance at $2.97–$3.01 (vs. ~3.11 consensus) and gave revenue guidance below the street, creating short‑term uncertainty about the cadence of 2026 growth. Read More.
• Negative Sentiment: Broader coverage highlighted investor “angst” and a bifurcated reaction — bullish on medium‑term fundamentals but worried about near‑term comps and valuation — keeping volatility elevated. Read More.

Analyst Ratings Changes

A number of research firms have recently commented on ABBV. Berenberg Bank set a $275.00 target price on AbbVie in a research report on Tuesday, January 20th. Piper Sandler reiterated an “overweight” rating and set a $289.00 price objective (up previously from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Scotiabank assumed coverage on shares of AbbVie in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective for the company. Raymond James Financial set a $256.00 target price on shares of AbbVie in a research report on Monday, November 3rd. Finally, HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and lifted their price target for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus target price of $251.00.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.